Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review

Authors: Anderson-Smits, C; Park, M; Bell, J; Mitchell, S; Hartley, L; Hawe, E

Affiliations: Takeda Development Center Americas, Inc., Cambridge, MA 02142, USA; RTI Health Solutions, Didsbury, Manchester, M20 2LS, UK.

Publication: Immunotherapy; February 2022

Abstract: AIM: Identify and describe published literature on the use of subcutaneous immunoglobulin (SCIG) as initial immunoglobulin (IG)-replacement therapy for patients with primary immunodeficiency diseases (PID). METHODS: We systematically identified and summarized literature in MEDLINE, Embase, BioSciences Information Service and Cochrane Library assessing efficacy/effectiveness, safety/tolerability, health-related quality-of-life (HRQoL) and dosing regimens of SCIG for IG-naive patients with PID. RESULTS: Sixteen studies were included. In IG-naive patients, SCIG managed/reduced infections and demonstrated similar pharmacokinetic parameters to IG-experienced patients; adverse events were mostly minor injection-site pain or discomfort. Three studies reported improvements in HRQoL. Quality of studies was difficult to assess due to limited reporting. CONCLUSION: Although studies were lacking, available data suggest IG-naive and IG-experienced patients initiating SCIG likely have similar outcomes.